Moore Capital Management, LP Bristol Myers Squibb CO Transaction History

Moore Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$46.4 - $67.43 $7.43 Million - $10.8 Million	-160,116 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$49.21 - $64.19 $1.95 Million - $2.55 Million	-39,709 Reduced 19.87%	160,116 $10.3 Million
Q3 2019 Nov 14, 2019	BUY	$42.77 - $50.71 $3.72 Million - $4.41 Million	86,910 Added 76.97%	199,825 $10.1 Million
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $2.34 Million - $2.58 Million	-52,337 Reduced 31.67%	112,915 $5.12 Million
Q1 2019 May 15, 2019	SELL	$45.12 - $53.8 $5.8 Million - $6.91 Million	-128,493 Reduced 43.74%	165,252 $7.88 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $14.3 Million - $18.6 Million	293,745 New	293,745 $15.3 Million
Q2 2018 Aug 14, 2018	SELL	$50.53 - $62.98 $9 Million - $11.2 Million	-178,083 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$59.92 - $68.98 $842,295 - $969,651	-14,057 Reduced 7.32%	178,083 $11.3 Million
Q4 2017 Feb 14, 2018	BUY	$59.94 - $65.35 $3 Million - $3.28 Million	50,115 Added 35.29%	192,140 $11.8 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $7.84 Million - $9.05 Million	142,025	142,025 $9.05 Million

2,404

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $115B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.